MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma.

Summary: Liver cancer is a tough disease to treat. A common drug called sorafenib works well at first, but over time, the cancer often figures out how to survive it. Scientists have discovered that a tiny molecule in the blood, called miR-22, controls how cancer cells use energy. When cancer cells change their energy habits, they can hide from the drug.

By checking the level of miR-22 in a patient's blood, doctors might soon be able to predict if sorafenib will keep working. Even better, researchers found that blocking a specific energy-absorbing protein (called GLUT1) can strip away the cancer's armor, allowing the drug to kill the cancer cells again. This discovery brings new hope for smarter, more effective liver cancer treatments!